Pharma’s shift
Swiss drugmaker Novartis plans to close its neuroscience research facility in Switzerland, but research on fragile X drugs will continue.
Efforts to ease the symptoms of autism are beginning to ramp up, with promising candidates in various stages of testing.
Swiss drugmaker Novartis plans to close its neuroscience research facility in Switzerland, but research on fragile X drugs will continue.
Researchers have uncovered cellular abnormalities in Timothy syndrome by regenerating neurons from individuals with the rare autism-related disorder, according to a study published 27 November in Nature Medicine.
A new technique efficiently screens for compounds that enhance or inhibit the formation of synapses, the junctions between neurons, according to a study published 25 October in Nature Communications.
People with autism may be picky eaters because they are hesitant to try new things, but also because they may have an atypical sense of taste.
A drug that blocks a type of receptor at the junctions between neurons reverses repetitive behaviors in a mouse model of autism, according to a new study.
Some forms of autism are caused by too many proteins at the synapse, the junction between neurons, whereas other forms result from too few, according to a study published 23 November in Nature.
Supplements of omega-3 fatty acids, prime ingredients of fish oils, don’t improve symptoms in children with autism, according to a new review.
The brain abnormalities characteristic of tuberous sclerosis may begin early in development and involve malfunctioning of neuronal precursors, according to studies of two different mouse models of the disorder published in October.
Researchers have derived neurons from stem cells to investigate mutations that lead to Rett and fragile X syndromes.
Oxytocin, the so-called ‘love hormone,’ plays a key role in monogamy in rodents, but its association with human relationships is subtle at best.